Natera, Inc.
NTRA
Classement en actions
#414
Natera, Inc. is a diagnostics company focused on developing and commercializing... Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.
Prix de l'action
$406.01
Dernière synchronisation: 2026-10-20
Capitalisation boursière
$58.52B
Changement (1 jour)
1.65%
Changement (1 an)
117.26%
Pays
US
Échange Natera, Inc. (NTRA)
Catégorie
Healthcare
Ratio P/E pour Natera, Inc. (NTRA)
Ratio P/E au October 2026 TTM : -290.26
Selon les derniers rapports financiers et le cours de l'action de Natera, Inc., le ratio P/E actuel (TTM) est de -290.26. À la fin de l’année 2023, le P/E de l’entreprise était de -16.57.
Historique du ratio P/E pour Natera, Inc. de 2012 à 2026
Ratio P/E à la fin de chaque année
| Année | Ratio P/E | Changez |
|---|---|---|
| 2026 (TTM) | -290.26 | 179.96% |
| 2024 | -103.68 | 525.80% |
| 2023 | -16.57 | 129.58% |
| 2022 | -7.22 | -59.75% |
| 2021 | -17.93 | -48.91% |
| 2020 | -35.09 | 86.94% |
| 2019 | -18.77 | 198.53% |
| 2018 | -6.29 | 78.85% |
| 2017 | -3.52 | -44.11% |
| 2016 | -6.29 | -14.08% |
| 2015 | -7.32 | -94.29% |
| 2014 | -128.17 | 620.30% |
| 2013 | -17.79 | 2,308.87% |
| 2012 | -0.74 | 0.00% |
Ratio P/E pour des entreprises similaires ou concurrentes
| Entreprise | P/E Ratio | Différence du P/E Ratio | Pays |
|---|---|---|---|
| 36.15 | -112.46% |
US
|
|
| 39.77 | -113.70% |
US
|
|
| - | - |
CN
|
|
| 34.18 | -111.78% |
US
|
|
| 32.24 | -111.11% |
US
|
Comment lire un P/E ratio ?
Le ratio Prix/Bénéfice (P/E Ratio) mesure la relation entre le cours de l'action d'une entreprise et ses bénéfices par action.
Un P/E bas mais positif indique une entreprise qui génère des bénéfices élevés par rapport à sa valorisation et qui pourrait être sous-évaluée. Un P/E négatif élevé (proche de 0) indique des pertes importantes.
Les entreprises avec un P/E supérieur à 30 ou négatif sont généralement considérées comme des "actions de croissance", ce qui signifie que les investisseurs s'attendent à ce qu'elles se développent ou deviennent rentables.
Les entreprises avec un P/E positif inférieur à 10 sont généralement considérées comme des "actions de valeur", car elles sont déjà très rentables mais avec peu de potentiel de croissance.